Liposarcoma
Oncology·MeSH: Liposarcoma
Prevalence
5.0 / 100K
6 drugs in development·5 companies·7 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| eribulin | DR REDDYS LABORATORIES LTD (RDY) |
Phase 2(3)
Phase 1(1)
| Drug | Company |
|---|---|
| Peposertib | Accustem Sciences Inc. (ACUT) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| pf-07220060 | PFIZER INC (PFE) |
Compare drugs
Frequently asked questions
How many drugs are in development for Liposarcoma?
BioSniper tracks 6 drugs in development for Liposarcoma across 5 companies.
How many clinical trials target Liposarcoma?
There are 7 clinical trials targeting Liposarcoma tracked by BioSniper.
What is the prevalence of Liposarcoma?
The estimated prevalence of Liposarcoma is approximately 5.0 per 100,000 population.
Deep-dive into Liposarcoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis